新型IRAK-4抑制剂化合物的合成和体外表征
Deepali Shrivastava1, Lavleen K Gupta2, Adinarayana Reddy Yerrapureddy2
1Department of Biotechnology, Vignan's Foundation for Science, Technology and Research, Vadlamudi, India.
Preparative biochemistry & biotechnology
|January 28, 2026
概括
四种新化合物有效抑制IRAK-4,这是自身免疫性疾病和败血症的关键标. 化合物IGYZT01058显示出最高的强度,表明其治疗潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 介素-1受体相关激酶4 (IRAK-4) 是炎症信号通路中的关键调解剂.
- 对IRAK-4的调节失调与自身免疫性疾病,癌症以及诸如败血症之类的严重感染有关.
研究的目的:
- 为了合成和评估其IRAK-4抑制活性的新化学实体.
- 在IRAK-4相关疾病中识别有力的IRAK-4抑制剂,用于潜在的治疗应用.
主要方法:
- * **化合物合成:**使用NMR光谱学合成和结构确认了四种新型化合物 (IGYZT01046,IGYZT01058,IGYZT01066,IGYZT01068).
- * **计算分析:**进行了分子对接研究,以评估与IRAK-4的结合亲和力.
- * **生物化学试验:**进行了酶抑制试验,以确定对IRAK-4的抑制潜力 (IC50值).
- * **药理动力学概况:** *在中*使用ADME预测来评估药理动力学特性.
主要成果:
- *所有四种合成的化合物都对IRAK-4表现出强烈的结合亲和力,结合能量低于-9.5 kcal/mol.
- *生物化学分析显示所有化合物的IRAK-4抑制活性显著,IC50值低于100nM.
- *化合物IGYZT01058表现出最高的强度,其IC50值为5.32nm.
- * *In silico* ADME预测表明了有利的药理动力学特征,包括良好的肠道吸收和血脑屏障透.
结论:
- *合成的化合物是IRAK-4的强有力的抑制剂.
- * IGYZT01058被确定为一个特别有前途的IRAK-4抑制剂.
- * 这些化合物具有作为治疗自身免疫性疾病和败血症的治疗药物的潜力.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
644
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
644
Synthesis and Decomposition Reactions
38.1K
Synthesis and decomposition are two types of redox reactions. Synthesis means to make something, whereas decomposition means to break something. The reactions are accompanied by chemical and energy changes.
38.1K
Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.2K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.2K
Synthesis of α-Substituted Carbonyl Compounds: The Stork Enamine Reaction
4.1K
α-Substituted ketones or aldehydes can be synthesized from enamines by the Stork enamine reaction, named after its pioneer Gilbert Stork. Enamines are useful synthetic intermediates where the lone pair on nitrogen is in conjugation with the C=C bond. They resemble enolate ions, as the resonance forms of both species have a nucleophilic α carbon.
4.1K
Molecules and Compounds
68.6K
Atoms and Molecules
68.6K


